DE4025499A1 - Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen - Google Patents

Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen

Info

Publication number
DE4025499A1
DE4025499A1 DE4025499A DE4025499A DE4025499A1 DE 4025499 A1 DE4025499 A1 DE 4025499A1 DE 4025499 A DE4025499 A DE 4025499A DE 4025499 A DE4025499 A DE 4025499A DE 4025499 A1 DE4025499 A1 DE 4025499A1
Authority
DE
Germany
Prior art keywords
fragments
cells
use according
derivatives
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE4025499A
Other languages
German (de)
English (en)
Inventor
Hans Dr Loibner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Sandoz Patent GmbH
Original Assignee
Sandoz AG
Sandoz Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG, Sandoz Patent GmbH filed Critical Sandoz AG
Priority to DE4025499A priority Critical patent/DE4025499A1/de
Priority to KR1019930700386A priority patent/KR930701193A/ko
Priority to CA002088370A priority patent/CA2088370C/en
Priority to AT91914884T priority patent/ATE136469T1/de
Priority to DE69118702T priority patent/DE69118702T2/de
Priority to JP3514194A priority patent/JPH06500771A/ja
Priority to PCT/EP1991/001510 priority patent/WO1992003165A1/en
Priority to HU9300349A priority patent/HUT64238A/hu
Priority to AU83932/91A priority patent/AU657489B2/en
Priority to EP91914884A priority patent/EP0547079B1/en
Priority to IE282391A priority patent/IE912823A1/en
Priority to ZA916313A priority patent/ZA916313B/xx
Priority to PT98622A priority patent/PT98622A/pt
Priority to TW080106337A priority patent/TW223019B/zh
Publication of DE4025499A1 publication Critical patent/DE4025499A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
DE4025499A 1990-08-11 1990-08-11 Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen Withdrawn DE4025499A1 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
DE4025499A DE4025499A1 (de) 1990-08-11 1990-08-11 Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen
KR1019930700386A KR930701193A (ko) 1990-08-11 1991-08-08 단클론성 항체의 신규한 용도
CA002088370A CA2088370C (en) 1990-08-11 1991-08-08 New use of monoclonal antibody
AT91914884T ATE136469T1 (de) 1990-08-11 1991-08-08 Neue verwendung eines monoklonalen antikörpers
DE69118702T DE69118702T2 (de) 1990-08-11 1991-08-08 Neue verwendung eines monoklonalen antikörpers
JP3514194A JPH06500771A (ja) 1990-08-11 1991-08-08 モノクローナル抗体の新規な用途
PCT/EP1991/001510 WO1992003165A1 (en) 1990-08-11 1991-08-08 New use of a monoclonal antibody
HU9300349A HUT64238A (en) 1990-08-11 1991-08-08 Method for producing of medical products containing monoclonal antibody br 55-2 or fragments thereof
AU83932/91A AU657489B2 (en) 1990-08-11 1991-08-08 Monoclonal antibody treats HIV-AIDS
EP91914884A EP0547079B1 (en) 1990-08-11 1991-08-08 New use of a monoclonal antibody
IE282391A IE912823A1 (en) 1990-08-11 1991-08-09 New use of a monoclonal antibody
ZA916313A ZA916313B (en) 1990-08-11 1991-08-09 New use of a monoclonal antibody
PT98622A PT98622A (pt) 1990-08-11 1991-08-09 Metodo de tratamento de infeccoes por hiv com um anticorpo monoclonal br55-2 ou um seu fragmento
TW080106337A TW223019B (https=) 1990-08-11 1991-08-12

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4025499A DE4025499A1 (de) 1990-08-11 1990-08-11 Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen

Publications (1)

Publication Number Publication Date
DE4025499A1 true DE4025499A1 (de) 1992-02-13

Family

ID=6412074

Family Applications (2)

Application Number Title Priority Date Filing Date
DE4025499A Withdrawn DE4025499A1 (de) 1990-08-11 1990-08-11 Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen
DE69118702T Expired - Lifetime DE69118702T2 (de) 1990-08-11 1991-08-08 Neue verwendung eines monoklonalen antikörpers

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69118702T Expired - Lifetime DE69118702T2 (de) 1990-08-11 1991-08-08 Neue verwendung eines monoklonalen antikörpers

Country Status (13)

Country Link
EP (1) EP0547079B1 (https=)
JP (1) JPH06500771A (https=)
KR (1) KR930701193A (https=)
AT (1) ATE136469T1 (https=)
AU (1) AU657489B2 (https=)
CA (1) CA2088370C (https=)
DE (2) DE4025499A1 (https=)
HU (1) HUT64238A (https=)
IE (1) IE912823A1 (https=)
PT (1) PT98622A (https=)
TW (1) TW223019B (https=)
WO (1) WO1992003165A1 (https=)
ZA (1) ZA916313B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0528767T3 (da) * 1991-08-21 2000-04-17 Novartis Ag antistofderivater
RU2208642C2 (ru) * 1992-05-22 2003-07-20 Новартис Аг МОНОКЛОНАЛЬНОЕ АНТИИДИОТИПИЧЕСКОЕ АНТИТЕЛО Ab2, СПОСОБ ЕГО ПОЛУЧЕНИЯ, ИСПОЛЬЗОВАНИЯ ПРОТИВ БОЛЕЗНЕЙ, СОПРОВОЖДАЮЩИХСЯ ЭКСПРЕССИЕЙ Lewis Y6 АНТИГЕНА, И ДЛЯ ОЧИСТКИ ВАРИАНТА BR55-2 АНТИТЕЛА, ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКИЙ СОСТАВ
ATE249846T1 (de) * 1998-06-29 2003-10-15 Wolfgang Bergter Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987003206A1 (en) * 1985-11-25 1987-06-04 Quash Gerard A Modified viral glycoproteins, diagnostic and therapeutic uses therefore
JPH083487B2 (ja) * 1987-07-31 1996-01-17 株式会社日本抗体研究所 異常応答リンパ球の検出方法並びにこれに用いる検出用試薬及びキット

Also Published As

Publication number Publication date
IE912823A1 (en) 1992-02-12
ZA916313B (en) 1993-04-28
WO1992003165A1 (en) 1992-03-05
AU657489B2 (en) 1995-03-16
CA2088370A1 (en) 1992-02-12
JPH06500771A (ja) 1994-01-27
EP0547079A1 (en) 1993-06-23
HU9300349D0 (en) 1993-05-28
HUT64238A (en) 1993-12-28
TW223019B (https=) 1994-05-01
EP0547079B1 (en) 1996-04-10
DE69118702D1 (de) 1996-05-15
ATE136469T1 (de) 1996-04-15
CA2088370C (en) 2003-03-25
PT98622A (pt) 1992-06-30
AU8393291A (en) 1992-03-17
KR930701193A (ko) 1993-06-11
DE69118702T2 (de) 1996-09-05

Similar Documents

Publication Publication Date Title
DE69430450T2 (de) Zell- und serum- proteinanker und konjugate
DE69216899T2 (de) Zytomodulierte Konjugate enthaltend spezifische Bindungspaargliedern
DE3850542T2 (de) Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
DE68913771T2 (de) Für IG-CD4 Fusionsproteine kodierende, klonierte Gene und deren Verwendung.
DE69527050T2 (de) Bispezifische moleküle mit klinischer verwendbarkeit
DE69128791T2 (de) Modifizierte antikörper mit kontrollierter clearance-zeit
DE69130561T2 (de) Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen
DE69719529T2 (de) Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems
DE3751214T2 (de) Monoklonale Antikörper gegen Immunglobulin G Fc-Rezeptoren auf humane mononukleare Phagozyten; bifunktionelle Antikörper; ziel-spezifische Effektorzellen; gezielte Makrophagen und Immunoassays.
DE69028739T2 (de) Modifizierte PF4-Zusammensetzung und Methoden zu deren Verwendung
DE69127749T2 (de) Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
US4676980A (en) Target specific cross-linked heteroantibodies
DE69032979T2 (de) Bispezifische heteroantikörper mit zweifachen effektorfunktionen
DE69231135T2 (de) CD2 bindender Bereich für das Lymphocyten-Funktion assoziierte Antigen-3
DE69621918T2 (de) Medikamente zur behandlung von autoimmunerkrankungen mit interferon-tau
DE69028684T2 (de) Gegen die beta-kette des leukozyten-adhäsions-rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung
DE69636015T2 (de) Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
DE602004005826T2 (de) Verfahren zur reinigung von stabilen radioiodium-konjugate
DE3686313T2 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
JPS62181280A (ja) トリコテセン結合体を含む抗腫瘍剤
DE69230643T2 (de) Methode zur behandlung von viralen infektionen
US5578706A (en) Methods and compositions concerning homogenous immunotoxin preparations
Ball et al. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/FcγRI (MoAb 32)
WO2000053633A2 (de) Antikörper- und chemokinkonstrukte, die gegen ccr5 gerichtet sind, und ihre verwendung in der behandlung von autoimmunkrankheiten
DE4025499A1 (de) Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen

Legal Events

Date Code Title Description
8130 Withdrawal